Nanobiotix 過去の業績

過去基準チェック /06

Nanobiotixの収益は年間平均-0.3%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間7.7% 66.8%割合で増加しています。

主要情報

-0.3%

収益成長率

14.3%

EPS成長率

Biotechs 業界の成長	-14.6%
収益成長率	66.8%
株主資本利益率	n/a
ネット・マージン	-79.3%
前回の決算情報	30 Jun 2024

Recent updates

収支内訳

Nanobiotix の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

DB:5NRA 収益、費用、利益 ( )EUR Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	42	-33	22	43
31 Mar 24	39	-37	22	40
31 Dec 23	36	-40	22	38
30 Sep 23	21	-49	21	36
30 Jun 23	7	-59	19	34
31 Mar 23	6	-58	18	33
31 Dec 22	5	-57	18	33
30 Sep 22	4	-50	18	32
30 Jun 22	3	-43	19	31
31 Mar 22	3	-45	19	31
31 Dec 21	3	-47	19	30
30 Sep 21	2	-45	19	29
30 Jun 21	2	-43	18	27
31 Mar 21	2	-39	16	26
31 Dec 20	2	-34	15	24
30 Sep 20	2	-41	16	27
30 Jun 20	2	-48	17	30
31 Mar 20	2	-49	18	30
31 Dec 19	3	-51	19	30
30 Sep 19	3	-46	17	28
30 Jun 19	3	-42	15	25
31 Mar 19	3	-36	14	23
31 Dec 18	3	-30	13	21
30 Sep 18	4	-28	12	20
30 Jun 18	4	-27	11	19
31 Mar 18	4	-26	11	19
31 Dec 17	4	-26	11	18
30 Sep 17	4	-25	12	16
30 Jun 17	4	-24	12	16
31 Mar 17	5	-23	11	16
31 Dec 16	5	-22	10	17
30 Sep 16	5	-21	10	16
30 Jun 16	5	-19	9	16
31 Mar 16	5	-18	8	15
31 Dec 15	4	-17	7	14
30 Sep 15	4	-15	7	12
30 Jun 15	3	-13	6	11
31 Mar 15	3	-11	5	9
31 Dec 14	3	-10	4	8
30 Sep 14	2	-9	4	7
30 Jun 14	2	-8	3	7
31 Mar 14	2	-8	4	6
31 Dec 13	2	-8	4	6

質の高い収益: 5NRAは現在利益が出ていません。

利益率の向上: 5NRAは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 5NRAは利益が出ておらず、過去 5 年間で損失は年間0.3%の割合で増加しています。

成長の加速: 5NRAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 5NRAは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -18.2% ) と比較することは困難です。

株主資本利益率

高いROE: 5NRAの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

Nanobiotix 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Recent updates

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06